# A2 Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/a2-biotherapeutics

- Industry: Biotechnology
- Headquarters: Agoura Hills, US
- Website: www.a2bio.com
- Total disclosed funding: $209M
- Latest round: Series C (Jan 9, 2025)
- Investors on record: 8

## About

A2 Biotherapeutics, Inc. is a US-based biotechnology firm focused on developing advanced cell therapies for solid tumors, utilizing its innovative Tmod™ precision-targeting platform to enhance treatment efficacy.Founded in 2018 and headquartered in Agoura Hills, California, A2 Biotherapeutics, Inc. develops T cell therapies aimed at treating various forms of solid tumors. The company was established by Michael Gallo, who has a background in leading biotech ventures. As of January 2025, A2 has raised a total of USD 80 mn through its Series C funding round, primarily from investors The Column Group and Samsara BioCapital, supporting the company's growth in the oncology field.A2 Biotherapeutics specializes in innovative cell therapies for solid tumors, focusing on its proprietary Tmod™ precision-targeting platform. This platform allows for a modular approach in identifying and targeting specific gene losses in cancer cells while sparing healthy cells. Their offerings include both autologous and allogeneic T cell therapies designed to overcome limitations of traditional therapies by integrating multiple signals. A2 Biotherapeutics markets its products to healthcare providers, oncology clinics, and research institutions across North America and Europe.A2 Biotherapeutics employs a structured revenue model based on partnerships with healthcare institutions and clinical trial collaborations. The company generates revenue through agreements with hospitals and research organizations, granting them access to advanced T cell therapy solutions. Revenue is primarily driven by clinical trial agreements and collaborations, along with potential tiered pricing structures related to the Tmod™ platform, aimed at establishing a sustainable revenue stream while promoting clinical advancements in oncology.Following its recent Series C funding round of USD 80 mn on January 9, 2025, A2 Biotherapeutics plans to utilize these funds to advance the clinical development of its CAR-T cell therapies and enhance pre-clinical programs. The company is focused on expanding its market presence in North America and Europe and aims to launch new products that leverage its Tmod™ platform to address additional cancer types. A2 Biotherapeutics is strategically positioned to enhance its offerings and potentially explore new geographic regions to optimize its impact in the oncology therapeutic landscape.

## Funding rounds

- Series C, Jan 9, 2025, $80M — The Column Group, Samsara BioCapital
- Series B, Oct 6, 2020, $72M — Regents of the University of California, The Column Group, Nextech, Hartford Healthcare Endowment, Casdin Capital, Vida Ventures, Euclidean Capital, Samsara BioCapital
- Series A, Nov 5, 2019, $57M — The Column Group, Nextech, Vida Ventures, Samsara BioCapital
- Seed, Jan 1, 2019 — Vida Ventures

## Investors

- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Seed, Series A, Series B
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A, Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B, Series C
- Regents of the University of California — Series B
- Hartford Healthcare Endowment — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Euclidean Capital — Series B